S-8 1 kiorapharmaceuticalsinc-sx.htm S-8 Document

As filed with the Securities and Exchange Commission on October 13, 2023
 

Registration No. 333-            
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 
 
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
 


 KIORA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)

 
 
Delaware 98-0443284
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
  
332 Encinitas Boulevard
Suite 102
Encinitas, CA
 92024
(Address of Principal Executive Offices) (Zip Code)

 
 
Kiora Pharmaceuticals, Inc. 2014 Equity Incentive Plan
(Full title of the plan)
 
 
Brian M. Strem, Ph.D.
President and Chief Executive Officer
Kiora Pharmaceuticals, Inc.
332 Encinitas Boulevard
Suite 102
Encinitas, CA 92024
(Name and address of agent for service)
 
 
(781) 788-9043
(Telephone number, including area code, of agent for service)
 
 
Copies to:

Robert A. Petitt
Burns & Levinson LLP
125 High Street
Boston, MA 02110
Telephone: (617) 345-3000



Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company . See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large Accelerated filer  Accelerated filer 
       
Non-accelerated filer ☒ Smaller reporting company ☒
       
    Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act . 
 
 
 
    
2

 INCORPORATION BY REFERENCE OF PRIOR REGISTRATION STATEMENT
 
This Registration Statement on Form S-8 is filed by Kiora Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), and relates to (i) 1,000,000 shares of its common stock, par value $0.01 per share (the “Common Stock”), issuable under the Registrant’s 2014 Equity Incentive Plan (as amended, the “2014 Plan”) that have become reserved for issuance pursuant to stockholder approval obtained on September 27, 2023, and (ii) 76,632 shares of Common Stock issuable under the 2014 Plan that became reserved for issuance as a result of the operation of the “evergreen” provision of the 2014 Plan, which provides that the total number of shares subject to such plan will be increased on January 1 of each of the ten (10) calendar years during the term of the 2014 Plan pursuant to a specified formula.
 
The shares of Common Stock included in this Registration Statement are in addition to the shares of Common Stock relating to the 2014 Plan that were registered on the Registrant’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on February 20, 2015 (SEC File No. 333-202207), on February 9, 2016 (SEC File No. 333-209441), on February 24, 2017 (SEC File No. 333-216227), on March 2, 2018 (SEC File No. 333-223431), on May 3, 2019 (SEC File No. 333-231207), on August 6, 2020 (SEC File No. 333-241657), on May 3, 2022 (SEC File No. 333-264640), and on October 5, 2022 (SEC File No. 333-267754) (together, the “Prior Registration Statements”).
 
This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding the Registration of Additional Securities. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as supplemented by the information set forth below.

 

    
3

 PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.
 
The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Commission. The following documents, which are on file with the Commission, are incorporated in this Registration Statement by reference:
 
(a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Commission on March 23, 2023 pursuant to Section 13 of the Exchange Act;
 
(b) All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and
 
(c) The description of the Registrant’s Common Stock contained in the Registrant’s Amendment No. 1 to Registration Statement on Form 8-A (File No. 001-36672) filed with the Commission on July 30, 2015 under the Exchange Act, including any amendment or report filed for the purpose of updating such description.
 
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.  
 
Item 8. Exhibits.
 
The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.
 

    
3

SIGNATURES
 
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Encinitas, State of California, on this 13th day of October, 2023.
 
 KIORA PHARMACEUTICALS, INC.
   
 By:/s/ Brian M. Strem, Ph.D.
  Brian M. Strem, Ph.D.
  President and Chief Executive Officer
 

POWER OF ATTORNEY AND SIGNATURES
 
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brian M. Strem, Ph.D. and Melissa Tosca, and each of them singly (with full power to each of them to act alone), as such person’s true and lawful attorney in fact and agent with full power of substitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.
 
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature Title Date
     
/s/ Brian M. Strem, Ph.D. President, Chief Executive Officer and Director October 13, 2023
Brian M. Strem, Ph.D. (principal executive officer)  
     
/s/ Melissa Tosca Executive Vice President of Finance October 13, 2023
Melissa Tosca (principal financial and accounting officer)  
     
/s/ Praveen Tyle Chairman October 13, 2023
Praveen Tyle    
     
/s/ Kenneth Gayron Director October 13, 2023
Kenneth Gayron    
     
/s/ David Hollander Director October 13, 2023
David Hollander    
     
/s/ Erin Parsons Director October 13, 2023
Erin Parsons    
     
/s/ Aron Shapiro  Director October 13, 2023
Aron Shapiro    
     
/s/ Carmine Stengone  Director October 13, 2023
Carmine Stengone    

    
4


INDEX TO EXHIBITS
  
Exhibit
Number
 Description
   
4.1 
   
4.2 
   
4.3 
   
4.4 
   
4.5 
   
4.6
4.7 
   
4.8 
   
5.1 
   
23.1 
   
23.2 Consent of Burns & Levinson LLP (contained in Exhibit 5.1 hereto)
   
24.1 Power of Attorney (contained on signature page hereto)
107
 

 
    
5